BYSI News and Press, BeyondSpring Inc. From 06/15/20

Edesa Biotech (NASDAQ: EDSA ) +218%  on launch of COVID-19 study in Canada. More news on: Edesa Biotech, Inc., Brickell Biotech, Inc., BioHiTech Global, Inc., Stocks on the move, , Read more ...

BeyondSpring (NASDAQ: BYSI ) announces positive results from a Phase 3 clinical trial, PROTECTIVE-2 , evaluating lead candidate Plinabulin, combined with Amgen's (NASDAQ: AMGN ) Neulasta (pegfilgrastim) compared to Neulasta alone for the treatment of chemo-induced neutropenia (low level...

-Met Primary Endpoint of Rate of Severe (Grade 4) Neutropenia Prevention in First Chemotherapy Cycle (Cycle 1) (p<0.01)- -Met Key Secondary Endpoint of Duration of Severe Neutropenia (DSN) of Cycle 1 (p<0.05)- -Met Key Secondary Endpoint of DSN in First Eight Days of Cycle 1...

Karyopharm Doses First Patient in Brain Cancer Trial Karyopharm Therapeutics ( KPTI ) announced that it has dosed the first patient for its Phase 1/2 clinical trial. The study aims to assess the potential of oral Selinexor in combination with standard of care therapy in treating patients...

BeyondSpring (NASDAQ: BYSI ): Q1 GAAP EPS of -$0.58 misses by $0.09 . More news on: BeyondSpring Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- PROTECTIVE-2 (Study 106) Phase 3 Interim Analysis This Month to Evaluate Superiority in CIN - - PROTECTIVE-2 Phase 2 Shows Positive Results in Chemotherapy Optimization with Potentially Better Clinical Outcomes - - DUBLIN-3 (Study 103 Phase 3) Second Interim Analysis for NSCLC R...

BeyondSpring ( BYSI -0.8% )  announces that its PROTECTIVE-2 (Study 106) Phase 2 superiority trial for chemotherapy-induced neutropenia (CIN) shows that Plinabulin, in combination with Neulasta improves dose and regimen compliance in patients treated with docetaxel, doxorubicin ...

- Plinabulin in Combination with Neulasta Improves Dose and Regimen Compliance of TAC Chemotherapy Compared to Neulasta Alone - - Chemotherapy Dose Reduction and Regimen Downgrade Significantly Impacts Long-term Survival - NEW YORK, June 09, 2020 (GLOBE NEWSWIRE) -- BeyondSpring ...

- DSMB Reviewed Over 500 Patients’ Data in Second Interim Analysis to Assess Overall Benefit / Risk with Plinabulin in Second- and Third-Line, EGFR Wild-Type NSCLC - - Data Continue to Support Plinabulin’s Immune Mechanism-Targeted Patient Selection - NEW YORK, June 03, ...

NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two Company abst...